Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Clinical applicability of urinary creatinine clearance for determining the initial dose of vancomycin in critically ill patients
This item is licensed under:Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Title: | Clinical applicability of urinary creatinine clearance for determining the initial dose of vancomycin in critically ill patients |
Authors: | Mikami, Ryusei Browse this author | Imai, Shungo Browse this author →KAKEN DB | Hayakawa, Mineji Browse this author →KAKEN DB | Sugawara, Mitsuru Browse this author | Takekuma, Yoh Browse this author →KAKEN DB |
Keywords: | Therapeutic drug monitoring | Vancomycin | Critically ill patients | Augmented renal clearance |
Issue Date: | 1-Feb-2022 |
Publisher: | Elsevier |
Journal Title: | Journal of infection and chemotherapy |
Volume: | 28 |
Issue: | 2 |
Start Page: | 199 |
End Page: | 205 |
Publisher DOI: | 10.1016/j.jiac.2021.10.008 |
Abstract: | Introduction: The purpose of this study was to evaluate the clinical applicability of urinary creatinine clearance (CrCl) for determining the initial dose of vancomycin (VCM) in critically ill patients and to assess VCM trough plasma concentration/maintenance daily dose (C/D) ratio in patients with augmented renal clearance (ARC). Methods: As the primary outcome measure, correlations between estimated renal function and the VCM C/D ratio were compared using the following formulas: CrCl, Cockcroft-Gault equation (eCrClC-G) and KineticGFR equation (KeGFR). Patients were divided into those with or without changes in renal function. The patients were further classified based on the presence or absence of ARC. The secondary outcome was the comparison of VCM C/D ratio between ARC and Non-ARC patients. Results: A total of 65 patients were enrolled for analysis. In all groups, CrCl tended to correlate better with the VCM C/D ratio than eCrClC-G and KeGFR. A significantly lower VCM C/D ratio was observed in patients with persistent ARC than in the Non-ARC group (0.24 versus 0.52 kg/L). Conclusions: The clinical applicability of CrCl for the initial dosing design of VCM in critically ill patients was shown. Furthermore, the results indicated that patients with persistent ARC required a higher VCM dose than Non-ARC patients. Although our findings are limited, they have a value for further verification. |
Rights: | © 2021. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/ | https://creativecommons.org/licenses/by-nc-nd/4.0/ |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/88121 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 武隈 洋
|